Desnitroetonitazene
Desnitroetonitazene (Etazen, Etazene, Etazone) is a benzimidazole derived opioid analgesic drug, which was originally developed in the late 1950s alongside etonitazene and a range of related derivatives. It is many times less potent than etonitazene itself, but still 70x more potent than morphine in animal studies. Corresponding analogues where the N,N-diethyl group is replaced by piperidine or pyrrolidine rings also retain significant activity (10x and 20x morphine respectively).[1] Desnitroetonitazene has been sold as a designer drug, first being identified in both Poland and Finland in March 2020.[2]
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C22H29N3O |
| Molar mass | 351.494 g·mol−1 |
| 3D model (JSmol) | |
| |
See also
References
- Hunger A, Kebrle J, Rossi A, Hoffmann K (1960). "Benzimidazol‐Derivate und verwandte Heterocyclen. II. Synthese von 1‐Aminoalkyl‐2‐benzyl‐benzimidazolen". Helvetica Chimica Acta (in German). 43 (3): 800–809. doi:10.1002/hlca.19600430323.
- "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.